The maker of the popular weight-loss drug Wegovy said Wednesday it is ramping up production of the drug, which has been in short supply in US pharmacies.

The drug faced widespread shortages last year due to its growing popularity, executives with drugmaker Novo Nordisk said on a call with investors on Wednesday.

“We know for sure that patients have been lining up,” company CEO Lars Jorgensen said on the call.

new nordisk saying on December 28 that all doses of the drug would be available again after supply issues, but added that it may take time for the drug to reach pharmacies from distribution centers.

There continues to be «pent-up demand» for Wegovy, but Novo Nordisk expects this to become less of a problem as more supply of the drug becomes available in the coming months, Jorgensen said.

“Obviously we are encouraged by the trend line that we see, but we also believe that there will be a normalization of that,” he said.

Wegovy, or semaglutide, is part of a class of drugs called GLP-1 agonists. They mimic a hormone that helps reduce food intake and reduce appetite. In clinical trials, Wegovy was shown to reduce body weight by about 15%.

The drug is expensive, costing about $1,300 a month, and insurance companies often don’t cover it.

The shortage of Wegovy has forced some people in the US to stop taking it, leading them to regain some or all of their weight.

Others have been prescribed Ozempic off-label for weight loss, causing shortages of that drug. Ozempic is the same drug as Wegovy, just in a lower dose, and is approved for use in people with type 2 diabetes to regulate their blood sugar levels. Both are manufactured by Novo Nordisk.

Doug Langa, head of North American operations for Novo Nordisk, noted on the call the difficulties patients have had finding the drug, but added that the company now «hopes» the drug will become more widely available.

Follow, continue NBC HEALTH in Twitter & Facebook.